



COMPANY OVERVIEW

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing REL-1017 (dextromethadone) in multiple indications. RELM-1017 is in Phase 2 for treatment resistant depression and preclinical testing for additional indications. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs.

RECENT NEWS

Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression

Jul 29 2019, 8:00 AM EDT

STOCK OVERVIEW

Symbol	RLMD
Exchange	OTCQB
Market Cap	94.78m
Last Price	\$2.85
52-Week Range	\$0.95 - \$3.418

09/19/2019 02:23 PM EDT

INVESTOR RELATIONS

Relmada Therapeutics, Inc.
Sergio Traversa
880 Third Avenue
12th Floor
New York, NY 10022
T: 646-876-3459
straversa@relmada.com

MANAGEMENT TEAM

Sergio Traversa
Chief Executive Officer

Dr. Ottavio Vitolo
Senior Vice President, Head of R&D and Chief Medical Officer

Gina DiGuglielmo
Vice President and Head of Clinical Operations

Charles S. Ence
Chief Financial Officer

RELMADA THERAPEUTICS, INC.

880 Third Avenue
12th Floor
New York, NY 10022
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.